ArticleVirchows Archiv : an international journal of pathology2006
Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Article in Virchows Archiv : an international journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Integrated Pathologic, Genomic, and Transcriptomic Analysis of Renal Neuroendocrine Tumors Reveals Neuroendocrine Transcriptional Programs and Associated Gastrointestinal-Type Epithelium in a Subset of Cases.Endocrine pathology · 2026Article
- Diagnostic and prognostic utility of insulinoma-associated protein 1, insulin gene enhancer protein 1, and secretagogin in pheochromocytoma.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Distribution of Nerve Fibers in Abdominal Wall Endometriosis and Their Clinical Significance.Journal of pain research · 2024Article
- Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.Virchows Archiv : an international journal of pathology · 2022Article
- Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.Endocrine pathology · 2020Article
- Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A.Oncology letters · 2020Article
- Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression.Oncology letters · 2019Article
- A TRPV1-to-secretagogin regulatory axis controls pancreatic β-cell survival by modulating protein turnover.The EMBO journal · 2017Article
- Article
- [Location and functions of secretagogin protein].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Article
- [Gastroenteropancreatic neuroendocrine neoplasms: concepts and related issues].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Review
- A retrospective study of the prevalence and classification of intestinal neoplasia in zebrafish (Danio rerio).Zebrafish · 2013Article
- The renaissance of Ca2+-binding proteins in the nervous system: secretagogin takes center stage.Cellular signalling · 2012Review
- Novel insights into the distribution and functional aspects of the calcium binding protein secretagogin from studies on rat brain and primary neuronal cell culture.Frontiers in molecular neuroscience · 2012Article
- Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study.Journal of clinical bioinformatics · 2011Article
- Secretagogin is a Ca2+-binding protein identifying prospective extended amygdala neurons in the developing mammalian telencephalon.The European journal of neuroscience · 2010Article
- The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.Journal of endocrinological investigation · 2008Review
- IMMUNOHISTOCHEMICAL MARKERS AND SPECT/CT SOMATOSTATIN-RECEPTOR (99MTC-TEKTROTYD) UPTAKE IN WELL AND MODERATELY DIFFERENTIATED NEUROENDOCRINE TUMORS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preliminary data suggest that secretagogin (SCGN), a calcium-binding protein identified from our previous proteomics study of colorectal cancers, is a potentially useful neuroendocrine marker. In this study, we further analyzed SCGN expression in normal and tumor tissues from various organ sites compared with three other conventional neuroendocrine markers [chromogranin A (CgA), neuron specific enolase, and synaptophysin]. We found strong SCGN staining in most normal neuroendocrine tissues except in the adrenal cortex. SCGN expression was identified in 140 out of 213 neuroendocrine tumors and 12 conventional carcinomas with neuroendocrine differentiation. In a subset of neuroendocrine tumors, such as gastric neuroendocrine cancers and typical carcinoid tumors of rectum and ovary, SCGN showed strong staining while CgA expression was often negative. It is intriguing to note that SCGN staining was positive in 26 out of 31 small cell lung cancers, more frequently than the other three markers. We conclude that SCGN is a novel neuroendocrine marker that may be useful in routine surgical pathology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.